Nidogen-2: a new serum biomarker for ovarian cancer.
OBJECTIVE
New ovarian cancer biomarkers suitable for early disease diagnosis, prognosis or monitoring could improve patient management and outcomes.


METHODS
Nidogen-2 was measured by immunoassay in serum of 100 healthy women, 100 women with benign gynecological conditions and 100 women with ovarian carcinoma.


RESULTS
Serum nidogen-2 concentration between normal and benign disease patients was not different (median, 13.2 and 12.1 mg/L, respectively). However, nidogen-2 concentration in serum of ovarian cancer patients was elevated (median, 18.6 mg/L; p<0.0001). Both nidogen-2 and CA125 were elevated more in serous histotypes of ovarian cancer and late state disease. Nidogen-2 and CA125 concentrations were strongly correlated. ROC curve analysis for nidogen-2 had an area under the curve (AUC) ranging from 0.73 to 0.83 but CA125 was superior (AUC ranging from 0.87 to 0.99). There was no complementarity between the two markers.


CONCLUSIONS
Nidogen-2 is a new biomarker for ovarian cancer which correlates closely with CA125.
Kuk
Cynthia
C
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Gunawardana
C Geeth
CG
Soosaipillai
Antoninus
A
Kobayashi
Hiroshi
H
Li
Lin
L
Zheng
Yingye
Y
Diamandis
Eleftherios P
EP
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D002135:Calcium-Binding Proteins; D015815:Cell Adhesion Molecules / Q000097:blood*; D005260:Female; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008875:Middle Aged; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000097:blood* / Q000473:pathology; D011506:Proteins / Q000378:metabolism; D012372:ROC Curve; D055815:Young Adult
D014408:Biomarkers, Tumor; D002135:Calcium-Binding Proteins; D015815:Cell Adhesion Molecules; D047908:Intracellular Signaling Peptides and Proteins; C549756:NBR1 protein, human; C114729:NID2 protein, human; D011506:Proteins